Mometasone furoate nasal spray (MFNS)

Phase 3

Sanofi (SNY)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Nov '26

SNYPhase 3$50.8B

Mometasone furoate nasal spray (MFNS) Phase 3 Est. Readout

Mometasone furoate nasal spray (MFNS)• Chronic Rhinosinusitis With Nasal Polyps210

Nov 2026~Confirmed

CT.gov

00%

Nov '26

SNYPhase 2$50.8B

Mometasone furoate nasal spray (MFNS) Phase 2 Est. Readout

Mometasone furoate nasal spray (MFNS)• Chronic Rhinosinusitis With Nasal Polyps60

Nov 2026~ConfirmedSTALE

CT.gov

00%

Competitive Landscape

0 competitors in Chronic Rhinosinusitis With Nasal Polyps

View Full Landscape

Drug Information

Target Indication

Chronic Rhinosinusitis With Nasal Polyps

Clinical Trial

NCT06834360

Last updated: 12/17/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

SNY

Sanofi

Pharmaceutical Preparations•Europe•NASDAQ

Related Pipeline

zolpidem-MR (SL800750)Phase 3

Sleep Initiation and Maintenance Disorders

efanesoctocog alfa (BIVV001)Phase 3

Hemophilia A

DuvakitugPhase 3

Ulcerative Colitis

xaliproden (SR57746A)Phase 3

Alzheimer Disease

A/H1N1 pandemic influenza vaccine (non- adjuvanted)Phase 3

Influenza

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts